Identification of Novel JAK2 Inhibitors from Amino Derivatives of Epoxyalantolactone: In Silico and In Vitro Studies
Duangjai Todsaporn, Kamonpan Sanachai, Chanat Aonbangkhen, Rungtiva P. Poo-arporn, Victor Kartsev, Sergey Pukhov, Svetlana Afanasyeva, Athina Geronikaki, Thanyada Rungrotmongkol · 2025
Read Identification of Novel JAK2 Inhibitors from Amino Derivatives of Epoxyalantolactone: In Silico and In Vitro Studies by Duangjai Todsaporn, Kamonpan Sanachai, Chanat Aonbangkhen, Rungtiva P. Poo-arporn, Victor Kartsev, Sergey Pukhov, Svetlana Afanasyeva, Athina Geronikaki, Thanyada Rungrotmongkol (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12786078.txt.
Description
Duangjai Todsaporn and eight colleagues hunt for new inhibitors of JAK2, a signaling enzyme that drives cervical cancer, starting from plant-derived sesquiterpene lactones. Computer docking screened forty derivatives. Scores for drug-likeness and toxicity cut the field to six, which the team made and tested.
Two compounds blocked JAK2 at low nanomolar levels, more strongly than the standard drug ruxolitinib, and killed cervical cancer cells while sparing others. Cell studies showed they triggered apoptosis, with a surge of reactive oxygen species. Computer models showed how they bind so tightly, through hydrogen bonds and hydrophobic contacts. The authors nominate both molecules as scaffolds for building therapy aimed at JAK2 for this cancer.
Catalog record
| CREATOR | Duangjai Todsaporn, Kamonpan Sanachai, Chanat Aonbangkhen, Rungtiva P. Poo-arporn, Victor Kartsev, Sergey Pukhov, Svetlana Afanasyeva, Athina Geronikaki, Thanyada Rungrotmongkol |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 48 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |